Will the Glivec decision slow innovation?
In the aftermath of the Glivec decision, multinational pharmaceutical companies are concerned about the status of the patent protection in India and are issuing dire warnings about impediments to drug development. Is there really cause for worry?
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: